Answers are grounded in this paper and cite their sources.
Type 2 diabetes occurs when the body cannot manage glucose efficiently and plasma glucose concentration remains high. This condition generally occurs due to deficiency of insulin or resistant against the insulin hormone. It affects a wide range of people from various socioeconomic sectors and ethnic groups. At least 462 million individuals worldwide have type 2 diabetes; with that number of people suffering from diabetes is expected to reach 693 million by 2045 globally. Due to the availability of a huge number of antidiabetic drugs in the market, still, there is a shortage of the effective and safe drugs in the market. This has raised concerns to find novel drugs. This study focused on finding novel drug a gainst the peroxisome proliferator-activated receptor gamma as a potential target. As it regulates lipid metabolism and glucose homeostasis. Molecular docking was done by AutoDock Vina for the identification of new potential drugs candidate against the peroxisome proliferator-activated receptor gamma. After docking, ligand suitability as a drug candidate also evaluated checking by ADME analysis. Forty docked compounds were evaluated for the pharmacological properties and also compare with standard drug compound. The results were observed that these compounds small litters samin, kobusin, methylpluviatilol, planinin, piperitol, and saltillin could be potential drug candidates for PPARG activation.
No takes yet. Share an insight, caveat, or question.
Allahabi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: